Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation

To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).

Inclusion Criteria:

• Male and female subjects equal or above 18 yrs old.
• Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
• Capability of understanding the purpose and risks of the study.
• Written informed consent

Exclusion Criteria:

• Fulminant hepatitis
• Kidney injury at baseline (Estimated Glomerular Filtration Rate < 50 ml/min in Modification of diet in renal disease-6) including hepatorenal syndrome
• Use of an induction agent Basiliximab at liver transplantation
• Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty